Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer's Dividend Yield Is Now 5%. Is the Stock a No-Brainer Buy for Income Investors?
09:37am, Wednesday, 25'th Oct 2023
The healthcare giant is struggling as demand drops for its COVID-19 products. The company projects that revenue could fall by as much as 42%.
Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. Roivant made $5 billion from the sale, after having only spent $15 million on development.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
09:01am, Tuesday, 24'th Oct 2023
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Pfizer hopes to avoid scaring investors when it reports 3Q results on Halloween
05:56pm, Monday, 23'rd Oct 2023
Pfizer Inc (NYSE:PFE) is scheduled to report earnings on October 31 before the opening bell, but if past results are any indication, the pharmaceutical giant's earnings won't be spooky. The Street
Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion
03:25pm, Monday, 23'rd Oct 2023
London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is co-owned by Pfizer (PFE), to Roche Holding for $7.1 billion.
Pfizer Stock: Interesting, If Discipline Returns
01:19pm, Monday, 23'rd Oct 2023
Pfizer Inc.'s acquisition of Seagen is the latest in a series of M&A deals fueled by pandemic-related profits. Despite the underperformance of Pfizer shares, the current share price shows potential ap
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
08:36am, Monday, 23'rd Oct 2023
Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billi
Morgan Stanley's Wilson: Next rally attempt will fail as investors are punishing earnings reports.
07:00am, Monday, 23'rd Oct 2023
Third-quarter earnings season has only just begun and Morgan Stanley's pessimistic market strategist Mike Wilson is already labelling it a disappointment.
Pfizer Just Announced Layoffs. Should You Still Buy the Stock?
09:45am, Saturday, 21'st Oct 2023
Pfizer is going to be trimming its headcount over the next 12 months. Its best-selling drugs of the last few years are no longer raking in lots of dough.
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
06:00am, Saturday, 21'st Oct 2023
Pfizer's revenue has taken a big hit because of lower COVID-19-related sales. Roche just released third-quarter earnings.
Is Pfizer a Bad News Buy Right Now?
05:15am, Saturday, 21'st Oct 2023
Pfizer recently cut its annual earnings guidance as demand for coronavirus products shrinks. Still, the company is in the middle of one of its most aggressive series of product launches ever -- aiming
Pfizer gets FDA green light for new shot that can streamline teenagers' vaccinations
03:57pm, Friday, 20'th Oct 2023
Pfizer Inc. PFE, -1.80% said Friday that the U.S. Food and Drug Administration has approved the first five-in-one vaccine designed to protect teenagers and young adults against meningococcal disease.
US FDA approves Pfizer's vaccine for meningococcal disease
03:41pm, Friday, 20'th Oct 2023
The U.S. Food and Drug Administration (FDA) has approved Pfizer's vaccine Penbraya, making it the first shot to protect against five groups of a deadly bacteria that can cause meningitis and blood poi
Pfizer jacks up price of five-day course of COVID drug Paxlovid to $1,400
11:45am, Friday, 20'th Oct 2023
The new cost of the drug is nearly triple the amount the US government paid during the coronavirus pandemic, according to a report.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
10:32am, Friday, 20'th Oct 2023
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
